相似文献
1
[Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
Z Rheumatol. 2005 May;64(4):286-9. doi: 10.1007/s00393-005-0752-2.
2
COX-2 inhibitors--a lesson in unexpected problems.
N Engl J Med. 2005 Mar 17;352(11):1131-2. doi: 10.1056/NEJMe058038. Epub 2005 Feb 15.
3
Raising the safety bar--the FDA's coxib meeting.
N Engl J Med. 2005 Mar 31;352(13):1283-5. doi: 10.1056/NEJMp058055.
4
Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Science. 2005 Feb 25;307(5713):1183-5. doi: 10.1126/science.307.5713.1183a.
5
Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
Ann Allergy Asthma Immunol. 2005 Jan;94(1):34-8. doi: 10.1016/S1081-1206(10)61282-3.
6
COX-2 inhibitors--lessons in drug safety.
N Engl J Med. 2005 Mar 17;352(11):1133-5. doi: 10.1056/NEJMe058042. Epub 2005 Feb 15.
7
COX-2 selective inhibitors and heart health.
Postgrad Med. 2005 Jan;117(1 Suppl):7-20. doi: 10.3810/pgm.01.2005.suppl40.201.
8
Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies.
Clin Ther. 2006 Jul;28(7):1022-34. doi: 10.1016/j.clinthera.2006.07.005.
9
COX-2 inhibitors and cardiovascular toxicity: a class effect?
S D J Med. 2005 Mar;58(3):93-4.
10
Learning the value of drugs--is rofecoxib a regulatory success story?
N Engl J Med. 2005 Mar 31;352(13):1285-7. doi: 10.1056/NEJMp048358.
引用本文的文献
1
Effects of Arachidonic Acid Metabolites on Cardiovascular Health and Disease.
Int J Mol Sci. 2021 Nov 6;22(21):12029. doi: 10.3390/ijms222112029.
Zotero 插件